We Claim:

5

10

15

20

- 1. A method of preparing a recombinant adenovirus (RAdEs) vaccine to protect against Japanese encephalitis virus (JEV) infection, wherein the said vaccine produces secretory envelop protein (Es) of JEV, said method comprising steps of:
 - a. digesting plasmid pMEs with restriction enzymes Kpn I and Bam HI to obtain cDNA encoding JEV proteins prM and Es,
 - b. ligating the cDNA to adenovirus shuttle plasmid pShuttle digested with restriction enzymes Kpn I and Hind III at the Kpn I end,
 - c. filling nucleotides at the free Bam HI and Hind III ends with T4 DNA polymerase to create blunt ends,
 - d. ligating the blunt ends together to yield shuttle plasmid pSEs with JEV
 cDNA encoding the proteins prM and Es,
 - e. digesting the shuttle plasmid pSEs with restriction enzymes I-Ceu I and Pl-Sce I to obtain expression cassette containing the JEV cDNA together with the CMV promoter/enhancer and BGH polyadenylation signal,
 - f. ligating the digested shuttle plasmid with I-Ceu I and Pl-Sce I digested adenovirus plasmid pAdeno-X to generate plasmid pAdEs containing Es expression cassette,
 - g. digesting the plasmid pAdEs with Pac I,
 - h. transfecting the monolayers HEK 293 cells with digested plasmid pAdEs for about one week, and
 - i. obtaining the recombinant virus RAdEs vaccine.
- 2. A method as claimed in claim 1, wherein the transfection is at about 37°C temperature.
 - 3. A method as claimed in claim 1, wherein the JEV proteins are under the control of human CMV IE promoter/enhancer.
 - 4. A recombinant adenovirus (RAdEs) vaccine, optionally along with pharmaceutically acceptable additives.
- 30 5. A vaccine as claimed in claim 4, wherein the vaccine produces secretory envelope protein of JEV.
 - 6. A vaccine as claimed in claim 4, wherein the vaccine protects against Japanese encephalitis virus (JEV) infection.

- 7. A vaccine as claimed in claim 4, wherein the vaccine is effective by intramuscular route of administration.
- 8. A vaccine as claimed in claim 4, wherein the additives are selected from a group comprising alum, gelatin and thiomersal.
- 5 9. A plasmid pAdEs of SEQ ID No. 1.
 - 10. Use of a pharmaceutically effective amount of recombinant virus RAdEs vaccine optionally along with additive(s) to the subject in need thereof for Japanese encephalitis virus (JEV) infection.
 - 11. Use as claimed in claim 10, wherein the method shows 100% efficacy.
- 10 12. Use as claimed in claim 10, wherein the method helps protect subject against encephalitis.
 - 13. Use as claimed in claim 10, wherein the subject is animal.
 - 14. Use as claimed in claim 10, wherein the subject is a human being.
- Use as claimed in claim 10, wherein the immunization activates both humoral and cell-mediated immune response.
 - 16. Use as claimed in claim 10, wherein the humoral response to the vaccine comprises IgG1 type of antibody.
 - 17. Use as claimed in claim 10, wherein the method leads to high amount of IFN-gamma secretion.
- 20 18. Use as claimed in claim 10, wherein immunization leads to moderate levels of IL-5 synthesis.
 - 19. Use as claimed in claim 10, wherein increased amount of RAdEs leads to higher immune response.
- 20. Use as claimed in claim 10, wherein the method is more effective than the commercially available vaccines.